Fennec Pharmaceuticals (FENC) EBITDA (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of EBITDA data on file, last reported at -$2.6 million in Q4 2025.

• Quarterly EBITDA fell 173.45% year-over-year to -$2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$6.3 million (down 344.67% YoY) and the FY2025 annual result came in at -$6.3 million, down 344.63% from the prior year.
• EBITDA fell to -$2.6 million in Q4 2025, from -$189000.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of $13.7 million in Q1 2024 to a low of -$7.9 million in Q3 2022.
• A 5-year average of -$2.8 million and a median of -$4.0 million in 2021 frame the typical range for EBITDA.
• The widest YoY moves for EBITDA: up 360.78% in 2024, down 411.5% in 2024.
• Tracing FENC's EBITDA over 5 years: stood at -$4.2 million in 2021, then sank by 45.83% to -$6.1 million in 2022, then surged by 70.37% to -$1.8 million in 2023, then soared by 48.62% to -$934000.0 in 2024, then plunged by 173.45% to -$2.6 million in 2025.
• The last three EBITDA figures came in at -$2.6 million (Q4 2025), -$189000.0 (Q3 2025), and -$2.7 million (Q2 2025), per Business Quant data.